A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
Abstract Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.214 |
| _version_ | 1797740031427739648 |
|---|---|
| author | Ahmed Elsada Amy Zalin‐Miller Craig Knott Leonidas Caravotas |
| author_facet | Ahmed Elsada Amy Zalin‐Miller Craig Knott Leonidas Caravotas |
| author_sort | Ahmed Elsada |
| collection | DOAJ |
| description | Abstract Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow‐up time of 6.4 months from T0, median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real‐world data provide useful clinical insight into a little‐studied patient population and highlight the poor outcomes in the UK setting. |
| first_indexed | 2024-03-12T14:05:50Z |
| format | Article |
| id | doaj.art-8c7a3d7ead32426fa7e402ef0d2fb940 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:05:50Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-8c7a3d7ead32426fa7e402ef0d2fb9402023-08-21T14:10:34ZengWileyeJHaem2688-61462021-08-012349349710.1002/jha2.214A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in EnglandAhmed Elsada0Amy Zalin‐Miller1Craig Knott2Leonidas Caravotas3Janssen UK High Wycombe UKHealth Data Insight CIC Cambridge UKHealth Data Insight CIC Cambridge UKJanssen UK High Wycombe UKAbstract Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow‐up time of 6.4 months from T0, median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real‐world data provide useful clinical insight into a little‐studied patient population and highlight the poor outcomes in the UK setting.https://doi.org/10.1002/jha2.214overall survivalreal‐world datarelapsed or refractory multiple myelomasalvage therapytriple‐class exposed |
| spellingShingle | Ahmed Elsada Amy Zalin‐Miller Craig Knott Leonidas Caravotas A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England eJHaem overall survival real‐world data relapsed or refractory multiple myeloma salvage therapy triple‐class exposed |
| title | A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England |
| title_full | A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England |
| title_fullStr | A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England |
| title_full_unstemmed | A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England |
| title_short | A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England |
| title_sort | registry study of relapsed or refractory multiple myeloma pre exposed to three or more prior therapies including a proteasome inhibitor an immunomodulatory agent and cd38 targeted monoclonal antibody therapy in england |
| topic | overall survival real‐world data relapsed or refractory multiple myeloma salvage therapy triple‐class exposed |
| url | https://doi.org/10.1002/jha2.214 |
| work_keys_str_mv | AT ahmedelsada aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT amyzalinmiller aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT craigknott aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT leonidascaravotas aregistrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT ahmedelsada registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT amyzalinmiller registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT craigknott registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland AT leonidascaravotas registrystudyofrelapsedorrefractorymultiplemyelomapreexposedtothreeormorepriortherapiesincludingaproteasomeinhibitoranimmunomodulatoryagentandcd38targetedmonoclonalantibodytherapyinengland |